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Abstract
Background: Stemless shoulder arthroplasty systems with uncemented metaphyseal fixation have been used for
glenohumeral osteoarthritis since 2004 (Hawi, et al. BMC Musculoskelet Disord 17:376, 2016). The stemless design
has several theoretical advantages compared with the stemmed shoulder arthroplasty systems: restoring patients’
anatomy; preserving humeral bone stock; and few complications in component removal if the need for a revision
arthroplasty arises. The purpose of the study is to compare the short-term, patient-reported outcome of stemless
and stemmed total shoulder arthroplasty (TSA).
Materials and methods: A randomized clinical trial will be conducted. Eighty patients with clinical and radiological
signs of primary or post-traumatic glenohumeral osteoarthritis, computed tomography (CT) scan-verified adequate
glenoid bone stock, and no total rupture of rotator cuff tendons verified by a magnetic resonance imaging (MRI)
scan will be randomly allocated to a stemless or stemmed TSA. The primary outcome will be the Western Ontario
Osteoarthritis Shoulder (WOOS) score at 12 months. Secondary outcomes are the WOOS score at three months and
the Oxford Shoulder Score (OSS) and EQ-5D at 3 and 12 months. All complications, including glenoid and humeral
component loosening, instability, rotator cuff tear, intraoperative and postoperative periprosthetic fracture, nerve
injury, infection, deltoid injury, and symptomatic deep venous thrombosis, will be reported.
Discussion: Findings will provide patients with better information about the potential benefits and harms of
stemless and stemmed TSA and will assist shoulder surgeons and patients in decision-making.
Trial registration: Clinicaltrials.gov, NCT03877315. Registered on 13 March 2019.
Keywords: Shoulder arthroplasty stemless, Non-stemmed, Shoulder prosthesis, Shoulder replacement, Shoulder
osteoarthritis, Metaphyseal fixation
Background
Glenohumeral joint osteoarthritis is a common cause of
shoulder pain, affecting up to one-third of patients aged >
60 years [1]. Surgical treatment is indicated for patients with
glenohumeral arthritis who continue to experience signifi-
cant symptoms despite an appropriate course of non-
operative management. Shoulder arthroplasty accounts for
the third most common joint replacement procedure after
hip and knee arthroplasty [2]. Based on data from the
National Patient Registry, the Statistical Department of the
Danish National Board of Health, the use of primary shoul-
der replacement in Denmark increased from 12 replace-
ments per 100,000 inhabitants in 2005 to 19 replacements
per 100,000 inhabitants in 2015 [3]. Glenohumeral osteo-
arthritis is now the most common indication for total shoul-
der arthroplasty (TSA) in Denmark [3].
Many different TSA designs are available on the market.
The stemless shoulder arthroplasty system with uncemen-
ted metaphyseal fixation has been used in Europe for gleno-
humeral osteoarthritis since 2004. The indications for
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anatomical stemless TSA are the same as for anatomical
stemmed TSA: osteoarthritis; rheumatoid arthritis; and
post-traumatic osteoarthritis or osteonecrosis.
The contraindications for anatomical stemless TSA are
acute proximal humerus fracture, inadequate metaphyseal
bone stock, and rotator cuff insufficiency [4, 5].
Stemless TSA has several theoretical advantages over
stemmed TSA: restoring patients’ anatomy (humeral shaft
angle, humeral head diameter, and lateralization); preserv-
ing humeral bone stock; and few complications in compo-
nent removal should the need of a revision arthroplasty
arise [6–8]. A recent review of 3360 anatomical TSAs
found an overall complication rate of 10.3% [8]. Peripros-
thetic fractures accounted for 6.7% and humeral compo-
nent loosening for 1.4% of all complications. Complications
related to the stemmed humeral component can be divided
into intraoperative (malpositioning, false route, peripros-
thetic fracture) and postoperative (loosening, migration,
disassembly, periprosthetic fracture, stem fracture) compli-
cations [9]. When a revision is necessary because of infec-
tion or periprosthetic fracture, the removal of a well-fixed
or cemented humeral component can be challenging and
lead to bone damage [10].
Few outcome studies on stemless TSA are available. A
recent review of 11 observational studies (published
2010–2016), incorporating a total of 929 patients, re-
ported comparable short- and mid-term functional out-
comes between stemmed and stemless shoulder
prosthesis [11]. Otherwise, there are few well-conducted
and adequately powered clinical studies.
The objective of this study is to increase knowledge about
shoulder function after operation with anatomical TSA by
comparing the patient-reported outcome after stemmed and
stemless anatomical TSA for glenohumeral osteoarthritis.
The Standard Protocol Items Recommendations for
Interventional Trials (SPIRIT) Statement 2013 has been
followed for the completion of this protocol (Table 1
and Additional file 1).
Methods/Design
Study design
An investigator-initiated, blinded (patient and data analyzer),
non-inferiority, randomized controlled clinical trial.
Material
Seventy-eight patients with shoulder osteoarthritis random-
ized to either stemmed or stemless shoulder prosthesis.
The flow of participants into the study are demonstrated in
Fig. 1
Inclusion criteria
1. Patients aged ≥ 18 years.
2. Patients have been referred to the Orthopedic
Department or Zealand University Hospital, Koege
or Hvidovre University Hospital for shoulder pain
during the study period.
3. Patients have the ability to read trial information in
Danish and give informed consent.
4. The diagnosis will be based on plain radiographs (at
least two perpendicular views), reduction of joint
space, and/or osteophyte formation.
5. Clinical presentation with pain at night and/or daily
pain, pain in overhead activity, and consumption of
pain medication.
Exclusion criteria
1. Previous shoulder surgery that involves the humeral
head and/or the glenoid cavity.
2. Patients with alcohol or drug abuse problems that can
compromise rehabilitation and follow-up appointments
as assessed by the recruiting surgeon at the first visit.
3. Patients unable to understand instructions in
Danish, follow the rehabilitation protocol, or
answer the questionnaires because of physical or
cognitive inabilities as evaluated by the recruiting
surgeon at the first visit.
4. Brachial plexus palsy.
5. Patients with previous fractures around the shoulder
(clavicle, scapula, and proximal humerus fractures).
6. Patients with magnetic resonance imaging (MRI)
scan-verified full thickness total tear of one or more
of the rotator cuff tendons.
7. Patients with computed tomography (CT) scan-
verified glenoid retroversion ≥ 20° that does not allow
glenoid component fixation without bone graft or
need an augmented glenoid component [12].
Eligibility
Patients referred with the diagnosis of “glenohumeral
osteoarthritis” will be examined by clinical examination
and plain radiographs to confirm the diagnosis. In the
case of glenohumeral osteoarthritis, which is to be
treated with TSA, the shoulder surgeon will offer the pa-
tient participation in the trial at the first visit; the patient
will be referred to routine shoulder CT and MRI scans
(which are already a part of standard shoulder osteoarth-
ritis protocol) and receive a folder with patient partici-
pant information and “Researchers rights in a health
science research project.”
Patients will have time to consider participation be-
fore the next visit (approximately one month) after
the first visit.
At the second visit, if the patients give their in-
formed consent for participation in the study, they
will receive three questionnaires to fill out while
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undisturbed in a room next door before handing
them to a secretary who will check that the ques-
tionnaires are completed before the patient leaves
the hospital.
The informed consent gives the primary investigator ac-
cess to information about the patient’s health condition from
the medical record, including data on age, sex, American So-
ciety of Anesthesiologists (ASA) score, previous shoulder
operations, and results from shoulder CTand MRI scans.
All surgical interventions will be undertaken at the
Zealand University Hospital Koege and Hvidovre Hos-
pital. A two-year recruitment period from 01 March
2019 to 01 January 2022 is planned.
Randomization and concealment of allocation
A computerized irreversible randomization application,
Research Electronic Data Capture (REDCap)© [13], will
allocate patients into two equal groups:
 Operated with stemmed shoulder arthroplasty,
Biomet Comprehensive® Total Shoulder System; and
 Operated with stemless shoulder arthroplasty,
Biomet Comprehensive® Nano Shoulder System.
The randomization sequence will be computer-generated
by block randomization (four in each block) and balanced
according to age in years (18–49, 50–59, 60–69, 70–79,
Table 1 Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) diagram
Stemmed group patients operated with stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System, Stemless group patients operated with
stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System WOOS Western Ontario Osteoarthritis Shoulder, OSS Oxford Shoulder Score, EQ-5D
the health status component of the EuroQol assessment
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80–89, 90–110), sex, and ASA score. The randomization
(patient allocation) will be performed on the trial laptop
computer in the operation room while the patient is being
anesthetized in the preparation room next door. The oper-
ating surgeon will obtain the allocation code by logging
onto the REDCap website after positioning the anesthetized
patient in a beach chair position. After randomization, the
patient’s allocation will be revealed to the operation team to
unpack the necessary operation tools and prosthesis.
Blinding
Patients will be blinded to which implant type they are
to receive. This will be done by not sharing the oper-
ation chart files with the patient’s online file records; the
inserted shoulder prosthesis will be noted by a unique
code in operation file, and the radiologist will be asked
not to describe the postoperative X-ray controls.
The primary investigator will conduct the blinded stat-
istical analysis supervised by the biostatistician.
Interventions
The operations will be performed by four shoulder sur-
geons familiar with the procedures of both shoulder
arthroplasty systems. All patients will be operated on
with the deltopectoral approach with subscapularis and
biceps tenodesis and instrumentation as described by
the manufacture [14].
All patients will receive standard pre- and periopera-
tive pain management, including general anesthesia and
interscalene peripheral nerve block performed by the
anesthesiologist.
Postoperative pain management will be adjusted re-
garding each patient’s needs and recorded. We do not
expect that individualized pain management will affect
our primary outcome measure one year after surgery.
Physiotherapy and self-training
All patients will receive a standardized rehabilitation pro-
gram at their local municipality service. The physiotherapist
in the hospital will demonstrate training protocol and in-
structions the day after surgery.
From 0 to 6 weeks, postoperative passive-to-active
unloaded movements in all directions are allowed, with
the following exceptions:
1. No external rotation is allowed in the first three
weeks. After three weeks, external rotation is
allowed until the feeling of capsular tightening;
2. No internal rotation of the operated arm behind the
back is allowed in the first six weeks.
Outcome measures
The primary outcome will be the Western Ontario Osteo-
arthritis Shoulder (WOOS) score at 12months [15].
The secondary outcomes will measure the following:
1. WOOS score at three months;
2. OSS at 3 and 12 months postoperatively [16];
3. General health status questionnaire EQ-5D at 3 and
12months [17].
At baseline, three-, and twelve-month visits, patients
will fill out questionnaires, WOOS, OSS, and EQ-5D,
alone before leaving the hospital (at the second visit after
accepting participation) and in the waiting room (at
three- and twelve-month visits) without interference
from the medical staff.
Fig. 1 CONSORT 2010 flow diagram. The expected flow of patients through the study. TSA total shoulder arthroplasty
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Follow-up
To ensure that the prosthesis is in situ, all patients will
undergo a conventional X-ray in two perpendicular
views before discharge. The discharge will be on day 1
or day 2 postoperatively, depending on the patient’s pain
and the need for recruiting social help service at home.
All patients will be followed actively for one year post-
operatively. Further follow-up including revision rates
will be recorded at five and ten years after surgery using
data from the Danish Shoulder Register (DSR).
Complications and adverse events that may have de-
veloped after the 12-month evaluation but that did not
lead to revision surgery will be extracted from the pa-
tient records (e.g. discharge letters, discharge diagnosis,
needed journal notes).
Outcome assessment tools
Western Ontario Osteoarthritis of the Shoulder Score
(WOOS)
The WOOS is a patient-administered, disease-specific
questionnaire for the measurement of the quality of life of
patients with osteoarthritis. It provides scores for four do-
mains: (1) physical symptoms; (2) sport, recreation, and
work; (3) lifestyle; and (4) emotions. Patients answer each
question using the visual analogue scale. The WOOS
score is calculated by measuring the distance from the left
side of the line and calculating the possible score in the
range of 0–100 (recorded to the nearest 0.5 mm.) It con-
sists of 19 questions; the total score is in the range of 0–
1900. A maximum score of 1900 signifies that the patient
has an extreme decrease in shoulder-related quality of life,
whereas a score of 0 signifies that the patient has no de-
crease in shoulder-related quality of life. The raw scores
are converted to a percentage of the maximum score for
simplicity of presentation. The questionnaire has been
translated into Danish and validated and tested on
patients with shoulder osteoarthritis [15, 18, 19].
Oxford Shoulder Score (OSS)
The OSS is a measurement tool for the assessment of
outcomes of shoulder surgery [16, 20]. It has been tested
and validated in patients with primary or secondary
osteoarthritis. The OSS is a 12-item questionnaire, with
each item scored in the range of 0–4; thus, the overall
score is the sum of the scores received for individual
questions. This results in a continuous score ranging
from 0 (most severe symptoms) to 48 (least severe
symptoms) [16]. For simplicity of presentation, the raw
scores will be converted to a percentage of the max-
imum score. We will use a validated Danish version [20].
EQ-5D
The EQ-5D, the health status component of the EuroQol
assessment (EuroQol Group, Rotterdam, The Netherlands),
is a generic instrument for describing and evaluating
health-related quality of life. The EuroQol instrument has
been designed for self-completion by the respondent.
The EQ-5D is a descriptive system comprising five di-
mensions in each of which the respondents describe
their health state: mobility; self-care; usual activities;
pain/discomfort; and anxiety/depression. Each dimen-
sion has five levels: no problems; slight problems; mod-
erate problems; severe problems; and extreme problems.
The patients are asked to indicate their health state by
ticking the box next to the most appropriate statement
in each of the five dimensions, which corresponds to a
one-digit number that expresses the level selected for
that dimension. The patient chooses one of five levels
for each dimension; thus, a five-digit number (EuroQol
Group 1990) can define the resulting health state. The
reliability and validity of the EQ-5D have been evaluated
in different patient populations, including the Danish
population, with the conclusion that the assessment had
good validity, reliability, and responsiveness [17, 21].
The EQ-5D demonstrated good internal and external re-
sponsiveness in patients with shoulder injuries and can
therefore be used as an outcome measure for evaluating
the HRQOL in both clinical studies and healthcare as-
sessments [22–24]. We received permission to use the
Danish version (permission ID number 27296) [25].
Patient dropout and protocol violations
Patients who drop out of the trial will be recorded and
the reason for dropout will be noted. The principal in-
vestigator will record and report any protocol violations.
Side effects and adverse events reporting
The department routinely uses both types of shoulder
prostheses. The treatments’ risks and disadvantages are
therefore not expected to differ from normal patient appli-
cation outside the trial. They include superficial infection,
deep infection, loosening of the prosthesis, nerve or vas-
cular injury during surgery, lack of healing, and prosthesis
migration. The amount of ionizing radiation to which the
patients are exposed during the CT scan and X-rays does
not differ from that for patients outside the study.
To assess possible complications after prosthesis inser-
tion, we will record any case of deep infection, nerve injury,
implant loosening (based on radiographic images), hetero-
topic ossification, instability, dislocation, implant removal,
and revision surgery or any adverse event that leads to
hospitalization one year after surgery. All complications will
be reviewed at the end of the trial and reported.
Statistical analysis plan
Sample size and power calculation
No existing studies report the minimal clinically import-
ant difference (MCID) of WOOS, but the MCID of the
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OSS was investigated and found to be 6 points or 12.5%
of a maximum score [26]. By extrapolating MICD from
OSS to WOOS, based on the known MCID for OSS, we
estimated the accepted clinically meaningful change
(ACMC) of WOOS to 237.5 points (12.5%).
With an ACMC of 12.5% and a standard deviation
(SD) of ±20.0, which we found from our retrospective
evaluation of patients operated with stemless TSA in
our department, we need to include 64 patients, 32 in
each group, to be 80% sure that the lower limit of a
one-sided 95% confidence interval will be above the
non-inferiority threshold of – 12.5%. With a loss of
follow-up assumption of 20%, a total of 78 patients is
required [27].
Hypotheses
We hypothesize the following:
 A one-year postoperative WOOS score for patients
operated with stemless TSA is inferior to that of pa-
tients operated with stemmed TSA by at least
ACMC = 237.5 (12.5%).
H0 : μstemmed > μstemless þ ACMC
 
 A one-year postoperative WOOS score for patients
operated with stemless TSA is not inferior to that of
patients operated with stemmed TSA by ACMC =
237.5 (12.5%).
HA : μstemmed≤μstemless þ ACMC
 
Data analysis
No interim data analysis will be carried out. The
primary investigator will enter data in the REDCap
database, and the principle investigator before the
data analysis will perform proofreading of a random
sample of 20 patients.
Data analysis will be conducted by a blinded biostatisti-
cian. Patients who drop out after the three-month evalu-
ation will be included in the analysis based on three months
of data (“last observation carried forward”). Patient dropouts
before the three months’ evaluation will not be included in
the analysis unless they participate in the one-year question-
naire evaluation. As suggested in the extension of the CON-
SORT statement for non-inferiority trial design, a per-
protocol analysis will be conducted and results obtained
[28, 29]. A questionnaire containing one or more missing
answers will be marked as incomplete; the patients will be
contacted by letter to answer the missing questions.
Descriptive statistics will be used to report demographic
data. Differences in demographic data and outcome mea-
sures between the two groups will be compared using chi-
square test for categorical variables; parametric (Student’s
t-test) or non-parametric (Mann–Whitney U-test) test for
continuous variables depending on the nature of data.
Data will be checked for possible extreme values before
the analysis. The statistical analyses will be performed
using SPSS version 25.0 (IBM Corp, Armonk, NY, USA)
[30]. The level of statistical significance is set at P < 0.05;
all P values are two-tailed. All complications, including
glenoid and humeral component loosening, glenoid wear
instability, rotator cuff tear, intraoperative and postopera-
tive periprosthetic fracture, nerve injury, infection, deltoid
injury, and deep venous thrombosis will be reported. Our
sample size does not give us enough power to allow
comparison.
Discussion
Through randomization and blinding, we aim to de-
crease the risk of bias. The use of usual care increases
the study’s validity and the results can be generalized for
the rest of this patient population. The current study will
provide high-quality evidence regarding the short-term
patient-reported outcome of stemless and stemmed
TSA. We will attempt to avoid the type-II error (when
hypothesis testing does not reject the null hypothesis,
even though the null should have been rejected) by
using a proper sample and by adding 20% to the sample
size compensating for dropouts. However, we will reduce
dropout bias by obtaining permission (at the first visit)
to call patients who do not show up for subsequent
visits. We will avoid selection bias through
randomization and reduce interviewer bias by letting pa-
tients answer the questionnaires without interference
from the medical staff and hand it back to the reception-
ist, who will check only that all the questionnaires are
filled out. Misclassification of non-differential informa-
tion bias of the outcome can affect the results in both
groups, but errors in outcome classification tend to be
less common and have much less impact on the estimate
of association. It tends to minimize any true difference
between the groups (bias toward the null). Using stem-
less rather than stemmed prosthesis regarding revision
surgery might have some advantages, but this study de-
sign does not allow us to investigate potential advantages
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Recruitment was initiated on 15 April 2019 and is ex-
pected to be finalized by 1 April 2022. (In case the target
number of 78 patients has not been met, the recruitment
period may be extended to reach the number required.)
The trial was registered on 13 March 2019 in clinical-
trials.gov (NCT03877315).
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Additional file 2: The Scientific Ethics Committee in Region Zealand,
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Additional file 3: Translated funding letter has obtained from the research
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Abbreviations
ACMC: Accepted clinically meaningful change; ASA: American Society of
Anesthesiologists Score; CT: Computed tomography; DSR: Danish Shoulder
Arthroplasty Register; MCID: Minimal clinically important differences;
MRI: Magnetic resonance imaging; OSS: Oxford Shoulder Score; TSA: Total
shoulder arthroplasty; WOOS: Western Ontario Osteoarthritis Shoulder
Acknowledgments
The authors would like to acknowledge all orthopedic specialists and nurses
at the Department of Orthopaedic Surgery, SUH-Koege, for their valuable in-
puts during the planning of this study. Special thanks to Dr. Tommy Henning
Jensen for his valuable contributions related to the surgical intervention and
enrolment of the participants.
Publication
This project result will be published in a peer-reviewed international journal
and the results will be presented at national and international conferences.
Authors’ contributions
ICMJE recommendations will be followed [32]: ZI: conception and design,
data collection and analysis, manuscript writing and final manuscript
approval. KS, JKP, and JVR: conception and design, critical revision and final
manuscript approval. SB: overall academic supervision, design, critical review
and final approval of the manuscript. All authors will read and approved the
final manuscript.
Funding
This trial is a part of a PhD study partly funded by the Zealand Region
Production, Research, and Innovation Department with tuition fees to the
University of Copenhagen. The Department of Orthopedics covers all trial
expenses as part of usual patient care settings. The Department of
Orthopedic Surgery at SUH-Koege has both prostheses available and no in-
dustrial funding is involved. Further external funding has been obtained from
the research foundation for health research of The Zealand Region (18–
000494) for the principal investigator’s (ZI) salary during research periods
(Additional file 3).
The current and future funders had no role in this study’s design and will
have no role in its execution, analysis, data interpretation, or decision to
submit results.
Availability of data and materials
All study-related information on participants will be stored securely on the
study site. All completed paper forms will be stored in locked file cabinets
before and after data are entered in the electronic database. Study data will
be collected and managed using REDCap electronic data capture tools
hosted in the Capital Region of Denmark [13]. REDCap is a secure, web-
based application designed to support data capture for research studies. All
electronic participants’ information will be stored on a secured study-specific
drive at the study site. Access to the study-specific drive will be limited to
users currently working on the project and will be restricted by individual
person-specific login and passwords. The primary investigator will keep an
updated list of persons with access to the study-specific drive.
Appointment schedules and any other listings linking participants to
additional identifying information will be stored separately in the hospital’s
secured intranet system or separate locked file cabinets in an area with
limited access. Study information will not be released outside of the study
without the permission of the relevant participant. The study is being
reported to and approved by the Danish Data Protection Agency and
adheres to the Act on Processing Personal Data.
Ethics approval and consent to participate
The study will be conducted according to the ethical principles outlined in
the Declaration of Helsinki [31]. Each patient who wants to be part of the
trial will be informed about the trial orally and in writing. Those who decide
to join the trial will be asked to sign an informed consent form. The
Scientific Ethics Committee in Region Zealand, Denmark has approved this
study protocol (approval reference number SJ-750), including the informed
consent form and patient information sheets (Additional file 2). We will, at all
times, respect the General Data Protection Regulation and Data Protection
Act. The processing of personal data has been approved by the Danish Data
Protection Agency (jr.no. REG-106-2018).
As participants in the trial, patients are covered by the insurance policies that
apply to ordinary treatment in the hospital; they may complain and receive
compensation following the rules in the Act on Complaints and
Compensation in the Health Services. All participants will be informed about




The authors declare that they have no competing interests.
Author details
1Department of Orthopedic Surgery, Zealand University Hospital, University
of Copenhagen, Koege, Denmark. 2Department of Orthopedic Surgery,
Herlev, Gentofte Hospital, University of Copenhagen, Herlev, Denmark.
3Department Of Orthopedic Surgery, Hvidovre Hospital, University of
Copenhagen, Hvidovre, Denmark.
Received: 19 March 2019 Accepted: 20 June 2019
References
1. Menge TJ, Boykin RE, Byram IR, Bushnell BD. A comprehensive approach to
glenohumeral arthritis. South Med J. 2014;107:567–73.
2. Zhang Y, Jordan J. Epidemyology of Osteoarthritis. Clin Geriatr Med. 2010;
26:355–69.
3. Danish shoulder arthroplasty register. 2016. https://www.sundhed.dk/
content/cms/3/4703_dsr_årsrapport2016.pdf. Accessed 7 Mar 2019.
4. Huguet D, DeClercq G, Rio B, Teissier J, Zipoli B. Results of a new stemless
shoulder prosthesis: Radiologic proof of maintained fixation and stability after a
minimum of three years’ follow-up. J Shoulder Elb Surg. 2010;19:847–52.
5. Berth A, Pap G. Stemless shoulder prosthesis versus conventional anatomic
shoulder prosthesis in patients with osteoarthritis: A comparison of the
functional outcome after a minimum of two years follow-up. J Orthop
Traumatol. 2013;14:31–7.
6. Churchill RS. Stemless shoulder arthroplasty: Current status. J Shoulder Elb
Surg. 2014;23:1409–14.
7. Spranz DM, Bruttel H, Wolf SI, Zeifang F, Maier MW. Functional midterm
follow-up comparison of stemless total shoulder prostheses versus
conventional stemmed anatomic shoulder prostheses using a 3D-motion-
analysis. BMC Musculoskelet Disord. 2017;18:478.
8. Bohsali KI, Bois AJ, Wirth MA. Complications of Shoulder Arthoplasty. J Bone
Joint Surg. 2017;4(3):410–9.
9. Zumstein MA, Pinedo M, Old J, Boileau P. Problems, complications,
reoperations, and revisions in reverse total shoulder arthroplasty: A
systematic review. J Shoulder Elb Surg. 2011;20:146–57.
10. Ahmadi S, Lawrence TM, Sahota S, Schleck CD, Harmsen WS, Cofield RH, et
al. The incidence and risk factors for blood transfusion in revision shoulder
Issa et al. Trials          (2019) 20:427 Page 7 of 8
arthroplasty: our institution’s experience and review of the literature. J
Shoulder Elb Surg. 2014;23:43–8.
11. Hawi N, Tauber M, Messina MJ, Habermeyer P, Martetschläger F. Anatomic
stemless shoulder arthroplasty and related outcomes: A systematic review.
BMC Musculoskelet Disord. 2016;17:376.
12. Malhas A, Rashid A, Copas D, Bale S, Trail I. Glenoid bone loss in primary
and revision shoulder arthroplasty. Shoulder Elb. 2016;8:229–40.
13. Harris PA, Thielke R, Gonzalez N, Conde JG, Taylor R, Payne J. Research
electronic data capture (REDCap)—A metadata-driven methodology and
workflow process for providing translational research informatics support. J
Biomed Inform. 2008;42:377–81.
14. Comprehensive Total Shoulder System. Zimmerbiomet. https://www.
zimmerbiomet.com/content/dam/zimmer-biomet/medical-professionals/
shoulder/comprehensive-total-shoulder-system/comprehensive-total-
shoulder-system-product-brochure.pdf. Accessed 7 Mar 2019.
15. Lo IKY, Griffin S, Kirkley A. The development of a disease-specific quality of life
measurement tool for osteoarthritis of the shoulder: The Western Ontario
Osteoarthritis of the Shoulder (WOOS) index. Osteoarthr Cartil. 2001;9:771–8.
16. Dawson J, Rogers K, Fitzpatrick R, Carr A. The Oxford shoulder score
revisited. Arch Orthop Trauma Surg. 2009;129:119–23.
17. Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: Past, Present and
Future. Appl Health Econ Health Policy. 2017;15:127–37.
18. Rasmussen J, Jakobsen J, Olsen BS, Brorson S. Translation and validation of
the Western Ontario Osteoarthritis of the Shoulder (WOOS) index – the
Danish version. Patient Relat Outcome Meas. 2013;4:49.
19. Moeini S, Rasmussen JV, Klausen TW, Brorson S. Rasch analysis of the
Western Ontario Osteoarthritis of the Shoulder index - the Danish version.
Patient Relat Outcome Meas. 2016;7:173–81.
20. Frich LH, Noergaard PM, Brorson S. Validation of the Danish version of
Oxford Shoulder Score. Dan Med Bull. 2011;58:A4335.
21. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a
Danish TTO value set for EQ-5D health states. Scand J Public Health. 2009;
37:459–66.
22. Jansson K-Å, Granath F. Health-related quality of life (EQ-5D) before and
after orthopedic surgery. Acta Orthop. 2011;82:82–9.
23. Olerud P, Tidermark J, Ponzer S, Ahrengart L, Bergström G. Responsiveness
of the EQ-5D in patients with proximal humeral fractures. J Shoulder Elb
Surg. 2011;20:1200–6.
24. Grobet C, Marks M, Tecklenburg L, Audigé L. Application and measurement
properties of EQ-5D to measure quality of life in patients with upper
extremity orthopaedic disorders: a systematic literature review. Arch Orthop
Trauma Surg. 2018;138(7):953–61. https://doi.org/10.1007/s00402-018-2933-x.
25. Gudex C, Sorensen J. EuroQol: Et generisk mål for helbredstilstand.
Månedsskrift Prakt Lægegerning. 1998;76:1339–45.
26. Christiansen DH, Frost P, Falla D, Haahr JP, Frich LH, Svendsen SW.
Responsiveness and minimal clinically important change: a comparison between
2 shoulder outcome measures. J Orthop Sport Phys Ther. 2015;45:620–5.
27. Randomisation and online databases for clinical trials. https://www.
sealedenvelope.com/power/continuous-noninferior/. Accessed 7 Mar 2019.
28. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, Pocock SJ, et al.
Reporting of Noninferiority and Equivalence Randomized Trials Extension of
the CONSORT 2010 Statement. JAMA. 2012;308:25.
29. Sanchez MM, Chen X. Choosing the analysis population in non-inferiority
studies: Per protocol or intent-to-treat. Stat Med. 2006;25:1169–81.
30. IBM SPSS Software. https://www.ibm.com/analytics/spss-statistics-software.
Accessed 8 Mar 2019.
31. The World Medical Association Inc. https://www.wma.net/policies-post/
wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-
human-subjects/. Accessed 7 Mar 2019.
32. ICMJE Recommendations for the Conduct, Reporting, Editing and P of SW
in MJ. 2018. http://www.icmje.org/icmje-recommendations.pdf. Accessed 7
Mar 2019.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Issa et al. Trials          (2019) 20:427 Page 8 of 8
